{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=10",
    "query": {
      "intervention": "Intramuscular vaccine",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 835,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:18:27.623Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01129362",
      "title": "Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "Pentacel® (DTaP-IPV/Hib)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Other Pertussis Vaccines",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "Up to 59 Months"
      },
      "enrollment_count": 1195,
      "start_date": "2010-02-08",
      "completion_date": "2014-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 2,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129362"
    },
    {
      "nct_id": "NCT02117570",
      "title": "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Associated Disease"
      ],
      "interventions": [
        {
          "name": "Clostridium difficile vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 185,
      "start_date": "2014-07",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 12,
      "location_summary": "DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Norfolk",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117570"
    },
    {
      "nct_id": "NCT03300050",
      "title": "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Vaccine"
      ],
      "interventions": [
        {
          "name": "cH8/1N1 LAIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03-adjuvanted cH5/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cH5/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03-adjuvanted cH8/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate buffered saline (PBS)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 65,
      "start_date": "2017-10-10",
      "completion_date": "2019-08-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300050"
    },
    {
      "nct_id": "NCT01644149",
      "title": "Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza Prophylaxis"
      ],
      "interventions": [
        {
          "name": "Stratis Jet Injector",
          "type": "DEVICE"
        },
        {
          "name": "Needle and Syringe",
          "type": "DEVICE"
        },
        {
          "name": "2011-2012 Fluzone trivalent inactivated influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "PharmaJet, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 83,
      "start_date": "2012-01",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2019-06-20",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644149"
    },
    {
      "nct_id": "NCT05220397",
      "title": "Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Recipient"
      ],
      "interventions": [
        {
          "name": "Janssen Ad26.CoV2.S Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reduction in Immunosuppression Medication",
          "type": "OTHER"
        },
        {
          "name": "Maintenance in Immunosuppression Medication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mark Stegall",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 468,
      "start_date": "2022-04-11",
      "completion_date": "2025-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220397"
    },
    {
      "nct_id": "NCT00063843",
      "title": "Anthrax-rPA: Safety, Tolerability, Immunogenicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "Recombinant Protective Antigen, Anthrax Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": null,
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2003-07",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063843"
    },
    {
      "nct_id": "NCT07177417",
      "title": "Characterizing the Human Airway Immune Response to FluMist Vaccination",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Young Adults",
        "Influenza Vaccines",
        "Influenza Vaccine Response"
      ],
      "interventions": [
        {
          "name": "FluMist",
          "type": "BIOLOGICAL"
        },
        {
          "name": "inactivated influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bronchoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-09-09",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07177417"
    },
    {
      "nct_id": "NCT02707692",
      "title": "Perturbing of HIV Reservoir With Immune Stimulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "AIDS",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Fluarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumovax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2016-08",
      "completion_date": "2022-01",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02707692"
    },
    {
      "nct_id": "NCT03692871",
      "title": "A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "90 Days",
        "sex": "ALL",
        "summary": "42 Days to 90 Days"
      },
      "enrollment_count": 2409,
      "start_date": "2018-12-14",
      "completion_date": "2021-03-26",
      "has_results": true,
      "last_update_posted_date": "2023-07-28",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 22,
      "location_summary": "Downey, California • Huntington Beach, California • San Diego, California + 18 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03692871"
    },
    {
      "nct_id": "NCT05596734",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "bivalent BNT162b2 (original/Omi BA.4/BA.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "qIRV (22/23)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bIRV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tIRV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1019,
      "start_date": "2022-10-28",
      "completion_date": "2023-12-28",
      "has_results": true,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-11-15T13:18:27.623Z",
      "location_count": 59,
      "location_summary": "Athens, Alabama • Phoenix, Arizona • Lake Forest, California + 40 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05596734"
    }
  ]
}